| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
|
J Clin Oncol
|
2005
|
3.62
|
|
2
|
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
|
J Clin Oncol
|
1998
|
1.42
|
|
3
|
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.
|
Cancer
|
2001
|
1.20
|
|
4
|
Estrogen receptor mutations in tamoxifen-resistant breast cancer.
|
Cancer Res
|
1994
|
1.17
|
|
5
|
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
|
Clin Cancer Res
|
2001
|
1.14
|
|
6
|
Prostacyclin therapy of thrombotic thrombocytopenic purpura.
|
Lancet
|
1980
|
1.05
|
|
7
|
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.
|
Adv Exp Med Biol
|
1999
|
0.97
|
|
8
|
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
|
Cancer
|
1983
|
0.96
|
|
9
|
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
|
Clin Cancer Res
|
2000
|
0.95
|
|
10
|
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.
|
J Clin Oncol
|
1988
|
0.90
|
|
11
|
Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.
|
Oncogene
|
2009
|
0.89
|
|
12
|
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.
|
Clin Cancer Res
|
1999
|
0.89
|
|
13
|
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
|
Clin Cancer Res
|
1998
|
0.88
|
|
14
|
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
|
Cancer Res
|
1991
|
0.88
|
|
15
|
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
|
J Clin Oncol
|
1997
|
0.87
|
|
16
|
Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
|
Invest New Drugs
|
2000
|
0.86
|
|
17
|
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.
|
J Clin Oncol
|
1987
|
0.86
|
|
18
|
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
|
Invest New Drugs
|
1984
|
0.84
|
|
19
|
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
|
J Clin Oncol
|
1994
|
0.83
|
|
20
|
Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience.
|
J Immunother (1991)
|
1991
|
0.82
|
|
21
|
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
|
Cancer
|
1992
|
0.82
|
|
22
|
Leiomyosarcoma of the main renal artery treated by laparoscopic radical nephrectomy.
|
Urology
|
2000
|
0.82
|
|
23
|
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
|
Cancer Chemother Pharmacol
|
2001
|
0.81
|
|
24
|
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
|
Invest New Drugs
|
2002
|
0.81
|
|
25
|
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
|
J Immunother
|
1997
|
0.80
|
|
26
|
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
|
Clin Cancer Res
|
1996
|
0.80
|
|
27
|
Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.
|
Cancer Chemother Pharmacol
|
1984
|
0.79
|
|
28
|
Pelvic computed tomography of breast carcinoma patients. Should it routinely be added to abdominal computed tomography?
|
Cancer
|
1997
|
0.77
|
|
29
|
Phase I trial of intraperitoneal chemotherapy with 5-fluorouracil and citrovorum factor.
|
Invest New Drugs
|
1986
|
0.77
|
|
30
|
Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastases.
|
J Surg Oncol
|
1983
|
0.77
|
|
31
|
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2000
|
0.77
|
|
32
|
Interleukin-2: use in solid tumors.
|
Stem Cells
|
1993
|
0.77
|
|
33
|
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma.
|
Cancer
|
1996
|
0.76
|
|
34
|
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer.
|
Invest New Drugs
|
1999
|
0.76
|
|
35
|
Hypercalcemia caused by metastatic adamantinoma: response to radiotherapy.
|
Sarcoma
|
1999
|
0.75
|
|
36
|
Estrogen receptor profile of patients with breast cancer metastatic to bone marrow.
|
J Surg Oncol
|
1983
|
0.75
|
|
37
|
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects.
|
J Immunother Emphasis Tumor Immunol
|
1993
|
0.75
|
|
38
|
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.
|
J Biol Response Mod
|
1990
|
0.75
|
|
39
|
Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer.
|
Am J Clin Oncol
|
1999
|
0.75
|
|
40
|
Web alert.
|
Curr Oncol Rep
|
2000
|
0.75
|
|
41
|
Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study.
|
Cancer Treat Rep
|
1986
|
0.75
|
|
42
|
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
|
J Immunother (1991)
|
1991
|
0.75
|
|
43
|
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
|
J Immunother Emphasis Tumor Immunol
|
1996
|
0.75
|
|
44
|
Web alert.
|
Curr Oncol Rep
|
2000
|
0.75
|
|
45
|
Phase I trial of natural human interferon beta in metastatic malignancy.
|
Cancer Res
|
1991
|
0.75
|
|
46
|
Web alert.
|
Curr Oncol Rep
|
2000
|
0.75
|
|
47
|
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
|
Leukemia
|
2005
|
0.75
|
|
48
|
Ifosfamide in the treatment of soft tissue sarcomas.
|
Semin Oncol
|
1996
|
0.75
|
|
49
|
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
|
J Cancer Res Clin Oncol
|
2001
|
0.75
|
|
50
|
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes.
|
J Immunother Emphasis Tumor Immunol
|
1993
|
0.75
|
|
51
|
Web alert.
|
Curr Oncol Rep
|
2000
|
0.75
|
|
52
|
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusions.
|
J Cancer Res Clin Oncol
|
1994
|
0.75
|
|
53
|
Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
|
Ann Thorac Surg
|
1995
|
0.75
|
|
54
|
Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
|
Am J Clin Oncol
|
1987
|
0.75
|
|
55
|
Web alert.
|
Curr Oncol Rep
|
2001
|
0.75
|
|
56
|
Initial observations and problems with in vitro predictive assay in genitourinary malignancies.
|
Urology
|
1984
|
0.75
|
|
57
|
A 47-year-old man with leiomyosarcoma and altered mental status.
|
Cleve Clin J Med
|
1999
|
0.75
|
|
58
|
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects.
|
J Immunother
|
2001
|
0.75
|
|
59
|
Web alert.
|
Curr Oncol Rep
|
2000
|
0.75
|